InNexus Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IXSBF research report →
About the company
InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology.
- CEO
- Angela Giannoccaro
- IPO
- 2005
- HQ
- Vancouver, CA
Price Chart
- Market Cap
- $12.63K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 189.86%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-6,688,684 · 16.57%
- EPS
- $-0.07 · 36.36%
- Op Income
- $-3,929,961
- FCF YoY
- 52.89%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -29.05
- Avg Volume
- 2.03K
Get TickerSpark's AI analysis on IXSBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IXSBF coverage
Recent articles, reports, and earnings notes.
No research on IXSBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IXSBF report →Similar companies
Peers in the same neighborhood.